Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.29Last Year’s EPS
-1.52Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 1.57%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Ultragenyx demonstrated strong revenue growth and impressive progress across its pipeline, particularly in global markets and late-stage clinical development. However, the company also reported a significant operating loss and cash usage, with some revenue variability noted. The forward-looking statements suggest confidence in achieving full-year GAAP profitability by 2027.Company Guidance
During Ultragenyx's Q1 2025 financial results call, the company provided guidance highlighting significant progress and expectations for the year. Revenue for the first quarter reached $139 million, a 28% increase compared to Q1 2024. Crysvita contributed $103 million to this total, with notable growth in Latin America and Turkey, achieving a 52% increase. The company reaffirmed its 2025 revenue guidance, projecting a total between $640 million and $670 million, representing 14% to 20% growth over 2024. Crysvita revenue is expected to range from $460 million to $480 million, and Dojolvi is projected to generate between $90 million and $100 million. The company also highlighted key clinical milestones, including the progress of the UX143 Phase 3 trial for osteogenesis imperfecta and other late-stage programs, and anticipated BLA submissions for DTX401 in mid-2025. Ultragenyx remains on track to achieve GAAP profitability by 2027.Strong Revenue Growth
Ultragenyx reported $139 million in revenue for Q1 2025, a 28% growth compared to Q1 2024. Crysvita contributed $103 million, marking a 25% growth over 2024, with a notable 52% growth in Latin America and Turkey.
Progress in Clinical Development
Significant progress was reported in multiple late-stage programs, including UX143 for osteogenesis imperfecta and GTX-102 for Angelman syndrome. Phase 3 trials are proceeding well, with key data readouts expected in 2026.
Global Commercial Expansion
The company expanded its global footprint, particularly in Latin America with Crysvita, and Europe and Japan with Evkeeza. Successful reimbursement negotiations in Brazil and Mexico are driving growth.
Pipeline Advancements
Two BLAs are in progress, with UX111 for Sanfilippo syndrome under FDA review and DTX401 for GSDIa on track for mid-2025 submission.
---
RARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $35.06 | $33.42 | -4.68% |
Feb 13, 2025 | $43.52 | $42.49 | -2.37% |
Nov 05, 2024 | $52.18 | $50.52 | -3.18% |
Aug 01, 2024 | $44.15 | $50.47 | +14.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ultragenyx Pharmaceutical (RARE) report earnings?
Ultragenyx Pharmaceutical (RARE) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Ultragenyx Pharmaceutical (RARE) earnings time?
Ultragenyx Pharmaceutical (RARE) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RARE EPS forecast?
RARE EPS forecast for the fiscal quarter 2025 (Q2) is -1.29.
---